Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Bowel (colorectal) cancer, Breast cancer, Lung cancer, Non small cell lung cancer (NSCLC), Oesophageal cancer, Ovarian cancer, Pancreatic cancer, Stomach cancer
Closed
Phase 1/2
This trial is looking at a drug called BAL101553 for advanced cancer. The trial is for people who have one of the following cancers and it has got worse or come back despite having other treatment
Cancer where the stomach joins the food pipe (gastro oesophageal junction cancer)
A type of breast cancer called triple negative breast cancer
Cells reproduce by dividing into 2. Before cells can divide, they create something called microtubules. These help the cells to separate. BAL101553 is a new drug that can stop cells dividing by damaging the microtubules. It is called a microtubule inhibitor. If cancer cells can’t split into 2, then the cancer can’t grow.
This is the first time BAL101553 has been tested in people. The aims of the trial are to
Find the highest safe dose of BAL101553
Learn more about what happens to the drug in your body
See if it helps people with advanced cancers
Recruitment start: 9 June 2011
Recruitment end: 18 December 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Rebecca Kristeleit
Basilea
Experimental Cancer Medicine Centre (ECMC)
University College London Hospitals NHS Foundation Trust
Last reviewed: 13 Jan 2016
CRUK internal database number: 7663
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
